摘要
为探讨我国成人急性淋巴细胞白血病（Ａ－ＡＬＬ）的有效治疗方案，提高我国Ａ－ＡＬＬ的疗效，设计了一个早期连续４个疗程无交叉耐药强化巩固治疗后再行自体骨髓移植（ＡＢＭＴ）治疗Ａ－ＡＬＬ的方案。共有３０例Ａ－ＡＬＬ患者（中位年龄２７岁）进入该方案的治疗观察，已有２０例完成全程治疗。结果：本方案的毒性可以耐受，近期疗效较好，ＡＢＭＴ后中位随访时间２８（４～７０）个月，３年无病生存率为６８．５％±１０．５％，复发率３０．８％±１２．５％。本资料初步表明，Ａ－ＡＬＬ在取得ＣＲ后早期进行较充分的强化巩固治疗后再行ＡＢＭＴ可以获得较好的疗效。本方案是治疗Ａ－ＡＬＬ的一个有效方案，值得推广。
To explore more effective modality for adult acute lymphoblastic leukemia(A-ALL),a protocol including continuous four courses of non-cross-resistant intensive chernotherapy followed by autologous bone marrow transplantation(ABMT)at early CR1 was designed.Thirty patients were enrolled,and 20 completed the treatment.At a median follow-up of 28 months(range,4 to 70 months),the diseasefree survival(DFS)and relapse rates at 3 years after ABMT were 68.5%±10.9%and 30. 8%±10.5%,respectively.The preliminary results suggested that ABMT following continuous intensive chemotherapy in early CR1 could produce prolonged DFS in A-ALL.
出处
《中华血液学杂志》
CSCD
北大核心
1996年第10期507-510,共4页
Chinese Journal of Hematology
关键词
急性
白血病
淋巴细胞性
骨髓移植
自体移植
Leukemia
acute
lymphoblastic Bone marrow transplantation
autologous Chemotherapy
intensive
